MX2010005105A - Ciclopentanos substituidos que comprenden actividad de prostaglandina. - Google Patents

Ciclopentanos substituidos que comprenden actividad de prostaglandina.

Info

Publication number
MX2010005105A
MX2010005105A MX2010005105A MX2010005105A MX2010005105A MX 2010005105 A MX2010005105 A MX 2010005105A MX 2010005105 A MX2010005105 A MX 2010005105A MX 2010005105 A MX2010005105 A MX 2010005105A MX 2010005105 A MX2010005105 A MX 2010005105A
Authority
MX
Mexico
Prior art keywords
prostaglanding
activity
substituted cyclopentanes
cyclopentanes
substituted
Prior art date
Application number
MX2010005105A
Other languages
English (en)
Spanish (es)
Inventor
Robert M Burk
Yariv Donde
Jeremiah H Nguyen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005105(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2010005105A publication Critical patent/MX2010005105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)
MX2010005105A 2007-11-09 2008-11-05 Ciclopentanos substituidos que comprenden actividad de prostaglandina. MX2010005105A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98684907P 2007-11-09 2007-11-09
US12/265,062 US9006464B2 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglandin activity
PCT/US2008/082469 WO2009061811A1 (en) 2007-11-09 2008-11-05 Substituted cyclopentanes having prostaglanding activity

Publications (1)

Publication Number Publication Date
MX2010005105A true MX2010005105A (es) 2010-05-27

Family

ID=40524829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005105A MX2010005105A (es) 2007-11-09 2008-11-05 Ciclopentanos substituidos que comprenden actividad de prostaglandina.

Country Status (21)

Country Link
US (1) US9006464B2 (enExample)
EP (1) EP2217581B1 (enExample)
JP (1) JP2011503089A (enExample)
KR (1) KR20100101097A (enExample)
CN (2) CN101952261B (enExample)
AR (1) AR069228A1 (enExample)
AU (1) AU2008324793B2 (enExample)
BR (1) BRPI0818902A2 (enExample)
CA (1) CA2705150C (enExample)
CL (1) CL2008003332A1 (enExample)
CO (1) CO6280480A2 (enExample)
DK (1) DK2217581T3 (enExample)
ES (1) ES2432058T3 (enExample)
IL (1) IL205604A (enExample)
MX (1) MX2010005105A (enExample)
NZ (1) NZ585517A (enExample)
RU (1) RU2481339C2 (enExample)
TW (1) TWI411438B (enExample)
UA (1) UA99840C2 (enExample)
WO (1) WO2009061811A1 (enExample)
ZA (1) ZA201003304B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP3991734B1 (en) 2019-06-28 2024-11-27 Gurus BioPharm Inc. Agent for the treatment of alopecia and promoting hair growth

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012A (en) * 1850-01-15 Improvement in mowing-machines
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
JPS5623984B2 (enExample) * 1973-04-19 1981-06-03
US4065472A (en) * 1975-09-29 1977-12-27 Pfizer Inc. 5-(2-Carboxythiophen-5-yl)-16-aryloxy-α-tetranor-ω-tetranorprostaglandins
GB1563201A (en) * 1975-11-05 1980-03-19 Shell Int Research Preparation of herbicidally acitve alanine derivatives
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6545045B1 (en) * 1998-12-24 2003-04-08 Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
WO2008094958A1 (en) 2007-02-01 2008-08-07 Allergan, Inc. Thiophene derivatives useful as medicaments for treating ocular hypertension

Also Published As

Publication number Publication date
DK2217581T3 (da) 2013-10-21
ZA201003304B (en) 2014-03-26
EP2217581B1 (en) 2013-07-31
RU2481339C2 (ru) 2013-05-10
CN101952261B (zh) 2013-06-12
TWI411438B (zh) 2013-10-11
WO2009061811A1 (en) 2009-05-14
CL2008003332A1 (es) 2011-08-12
AR069228A1 (es) 2010-01-06
CA2705150A1 (en) 2009-05-14
EP2217581A1 (en) 2010-08-18
CA2705150C (en) 2016-06-14
IL205604A (en) 2014-06-30
IL205604A0 (en) 2010-11-30
US9006464B2 (en) 2015-04-14
US20090124676A1 (en) 2009-05-14
CO6280480A2 (es) 2011-05-20
UA99840C2 (ru) 2012-10-10
KR20100101097A (ko) 2010-09-16
WO2009061811A8 (en) 2009-07-02
JP2011503089A (ja) 2011-01-27
AU2008324793B2 (en) 2013-12-05
TW200934500A (en) 2009-08-16
NZ585517A (en) 2012-08-31
CN102977048A (zh) 2013-03-20
BRPI0818902A2 (pt) 2015-05-12
ES2432058T3 (es) 2013-11-29
CN101952261A (zh) 2011-01-19
RU2010122681A (ru) 2011-12-20
AU2008324793A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
TN2011000172A1 (en) Therapeutic antiviral peptides
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
WO2008005266A3 (en) Method of using substituted piperidines that increase p53 activity
WO2007135527A3 (en) Benzimidazolyl compounds
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
TW200745084A (en) Novel compounds
IN2012DN03182A (enExample)
DE602007014036D1 (de) 12-aryl-prostaglandin-analoga
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
MY145795A (en) Pyrazoline compounds
UA99840C2 (ru) Замещенные циклопентаны, которые имеют простагландиновую активность
GB2461659A (en) Structured compositions comprising a clay
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
MX2009001578A (es) Lactamas terapeuticas.
TW200738627A (en) Trialkylsilyl-indoles
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009013545A3 (en) Chemical compounds
WO2009124962A3 (en) Sulfonamides
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
WO2010123959A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
PH12014500561A1 (en) Phenyl derivative
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
FG Grant or registration